The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans

The American Review of Respiratory Disease
J W LammersP J Barnes


In a double-blind randomized study, we compared the effects of the M1-selective muscarinic receptor antagonists pirenzepine and the nonselective antagonist ipratropium bromide on bronchoconstriction induced by inhaled sulfur dioxide (SO2) and methacholine in atopic volunteers. Both inhaled pirenzepine (70 micrograms) and ipratropium bromide (7 micrograms) significantly inhibited vagally mediated bronchoconstriction by SO2 to the same extent (p less than 0.02). However, at this dose, pirenzepine had no effect on methacholine-induced bronchoconstriction, whereas ipratropium bromide gave significant protection (p less than 0.02). This indicates that vagally mediated bronchoconstriction in humans can be inhibited by blockade of pirenzepine-sensitive (M1) muscarinic receptors probably present on a different site from muscarinic receptors at the neuromuscular junction and presumably localized to parasympathetic ganglia. Pirenzepine may be useful in investigating ganglionic function and could be beneficial therapeutically in airway disease.


May 19, 1989·European Journal of Pharmacology·J C Mak, P J Barnes
May 3, 1990·European Journal of Pharmacology·M Eltze
Feb 14, 1991·European Journal of Pharmacology·Z J Yang, D F Biggs
Nov 14, 1994·European Journal of Pharmacology·R E HowellK D Laemont
Jan 1, 1990·Molecular Aspects of Medicine·P J Barnes
Feb 1, 1993·Pharmacology & Therapeutics·Y D Pendry
Oct 18, 2000·European Journal of Pharmacology·A D KraneveldF P Nijkamp
May 1, 1995·The Journal of Allergy and Clinical Immunology·M V White
Nov 20, 2001·Current Opinion in Pharmacology·A M LeeA D Fryer
May 1, 1990·Acta Anaesthesiologica Scandinavica·Y SugaiM Miyazaki
Dec 12, 2012·Mediators of Inflammation·George Karakiulakis, Michael Roth
May 24, 2001·American Journal of Respiratory and Critical Care Medicine·L S OnR W Costello
Aug 26, 2006·American Journal of Respiratory and Critical Care Medicine·Yukiko MaedaMasaharu Nishimura
Sep 29, 2011·Future Medicinal Chemistry·Jakob Busch-Petersen, Dramane I Lainé
Jul 1, 1994·The Veterinary Quarterly·R A van NieuwstadtH J Breukink
Oct 28, 1999·Drug and Chemical Toxicology·D L AllenR K Wolff
Mar 8, 2014·Journal of Veterinary Pharmacology and Therapeutics·A MenozziS Bertini
Dec 3, 2016·Nature Reviews. Drug Discovery·Rita SantosJohn P Overington
Jun 29, 2004·Pulmonary Pharmacology & Therapeutics·K Racké, S Matthiesen
Jul 20, 2002·The Annals of Otology, Rhinology, and Laryngology·Muneo NakayaNobuo Usui
Aug 19, 2007·Journal of Internal Medicine·Kjell Larsson
Jan 1, 2010·Expert Review of Clinical Pharmacology·Dramane I Lainé
Aug 1, 1989·Postgraduate Medical Journal·P J Barnes
Mar 4, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Michael T BorchersJ J Lee
Apr 12, 2008·Acta Oto-laryngologica. Supplementum·Muneo NakayaKimitaka Kaga


Jul 1, 1976·Journal of Applied Physiology·F J LándsérK P van de Woestijne
Dec 29, 1987·Neuroscience Letters·C J van KoppenC A van Ginneken
Dec 1, 1984·British Journal of Pharmacology·A D Fryer, J Maclagan

Related Concepts

Inhalation of Drugs
Dermatitis, Atopic
Ipratropium Bromide
Sulfur Dioxide
Antagonist Muscle Action
Structure of Parasympathetic Ganglion
Vagus Nerve Structure

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.